A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July 2014 issue of the journal “EMBO” by Prof David Andrew Sinclair, North BJ, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule–based Lifespan extension therapy: E6AP extends mammalian life span via up regulation of its target gene BubR1. Thus, pharmacological formulations encompassing “E6AP activators or small molecule compounds that increase both E6AP and BubR1“ may be used to extend the lifespan of an individual.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How E6AP increases the expression of BubR1
To cite: Boominathan, Small molecule-based Lifespan extension therapy: E6AP extends mammalian life span via up regulation of its target gene BubR1, 21/May/2015, 22.49, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation